An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer


Hauptsponsor: Epimmune

Quelle Epimmune
Kurze Zusammenfassung

EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.

Gesamtstatus Completed
Anfangsdatum February 2003
Phase Phase 1
Studientyp Interventional
Einschreibung 18

Interventionsart: Biological

Interventionsname: EP2101



Inclusion Criteria:

- Confirmed diagnosis of Colon Cancer, stage III

- At least four weeks following prior standard treatment, with no evidence of disease

- Must use adequate birth control

Exclusion Criteria:

- Prior cancer vaccine therapy or concurrent participation in any other investigational study

- A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment

- A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine

- Women who are pregnant, intend to become pregnant, or who are breast feeding

Geschlecht: All

Mindestalter: 18 Years

Maximales Alter: N/A

Gesunde Freiwillige: No

University of Southern California School of Medicine | Los Angeles, California, 90033, United States
University of California, San Diego | San Diego, California, 92037, United States
Cancer Centers of Florida | Orlando, Florida, 32806, United States
New York Oncology Hematology | Albany, New York, 12208, United States
Duke University Medical Center | Durham, North Carolina, 27710, United States
Mary Crowley Medical Research Center | Dallas, Texas, 75246, United States
Tyler Cancer Center | Tyler, Texas, 75702, United States
University of Washington | Seattle, Washington, 91895, United States
Cancer Care Northwest | Spokane, Washington, 99218, United States
Standort Länder

United States


April 2004

Bedingung Durchsuchen
Studiendesign Info

Zuweisung: Non-Randomized

Interventionsmodell: Single Group Assignment

Hauptzweck: Treatment

Maskierung: None (Open Label)